Update 17-Jul-2020

 

COVID-19 (SARS-CoV-2) Molecular Testing

 

Chan & Hou Medical Laboratories Ltd. is one of the COVID-19 testing laboratories recognized by HKSAR Government: (https://www.info.gov.hk/gia/general/202007/16/P2020071600879.htm)

 

 For COVID-19 RT-PCR test, we are pleased to offer both routine and express testing. *Please note that referral from a registered medical doctor is a must.*

 

COVID-19 RT-PCR Test

 

Result time:

  • Routine testing: Available in 24-48 hour
  • Express testing: Same day result available, with specimen dropoff cutoff at 10:00am

Specimen accepted: Deep Throat Saliva

 

Procedure:

1) Obtain a doctor referral letter

2) Make an appointment in one of our centres:

  • Central: 2522-1860
  • Jordan: 2782-1096
  • Shatin: 2602-5015

3) Collect specimen collection kit in advance (at least 1 day in advanced) from one of our branches

4) Take a deep throat saliva sample by yourself upon waking up, before brushing teeth & eating.

5) Submit the sample to one of our branches and settle the payment. The specimen must be double bagged, with referral form placed in the kangaroo pocket of the outer specimen bag. Please bring along your identification document e.g. HKID,passport or other travel document.

 

*Please note Chan & Hou will report all positive case to the Centre for Health Protection*

 


 

 

Update: 10-Jun-2020

 

New in-house test : Prostate Health Index (PHI 前列腺健康指數組合)

 

 

Prostate cancer is the fourth leading cause of male cancer in Hong Kong and the incidence is increasing at the fastest rate among all cancers affecting men. Although total Prostate-Specific Antigen (PSA) test is widely used as a screening tool for prostate cancer, its level will also be affected by benign prostatic conditions (e.g. benign prostatic hyperplasia, prostatitis) and often leads to unnecessary prostate biopsies.

 

Prostate Health Index (PHI) is a score calculated from the 3 PSA isoforms {PSA, free PSA, p2PSA}. The higher the PHI score, the higher probability of finding clinically-significant prostate cancer upon prostate biopsy. This test has the following advantages:

 

  • In 2012, the US Food and Drug Administration (FDA) has approved PHI as a screening tool of prostate cancer in men above 50 years old with a PSA level of 2 - 10 ng/mL and normal DRE.

  • Local studies have shown that PHI is a good predictor of prostate biopsy outcome. With a better sensitivity and specificity, PHI is useful to avoid over 40% of unnecessary prostate biopsies in patients with PSA level of 2 – 10 ng/mL. (#)

  • PHI is not only a useful predictor of prostate biopsy outcome, it also identifies high-grade disease, predict adverse treatment outcome as well as aid to select the right candidate for active disease surveillance. It offers a better risk stratification and helps clinicians with a better clinical management of their patients. (&)

  

 

# Special test:

Prostate Health Index

Include: Total PSA, Free PSA, p2PSA, % Free PSA and PHI}

Specimen requirement: In Lab
TAT 3 working days

 

 

 

# Ng CF et al. (2014) The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol

^ Chiu PK, Ng CF et al. (2018) A multi-centre evaluation of the role of Prostate Health Index (PHI) in regions with different prevalences of prostate cancer: A different reference range is needed for European and Asian. European Urology Supplements

& Lepor A et al. (2016) The Prostate Health Index : Its Utility In Prostate Cancer Detection. Urol Clin North Am.

 

 


 

Update: 29-Jan-2020
*Click here to visit FluTest.hk by Roche*

 

New Test: Influenza A/B & RSV Molecular Assay

(甲型, 乙型流感病毒及呼吸道合胞病毒快速分子測試)

 

In regards to the winter peak flu season in Hong Kong, we have now launched the Influenza A/B & RSV Molecular Assay, which will replace our current Influenza A & B Antigen test.

 

Influenza A and B viruses together with respiratory syncytial virus (RSV) are among the main causes of acute respiratory viral infections1. This new CE-IVD test demonstrates excellent performance (high sensitivity and specificity with average 98% positive and negative agreement)2to detect and differentiate these three viruses within short turn-around-time. Fast and reliable results can facilitate diagnosis, effective clinical management within the 42-hour golden period which is feasible to reduce severe or fatal complications for young, elderly and immuocompromised patients3,4.

 

**The mortality and morbidity risks associated with influenza and RSV are much higher among children (under the age of five), elderly (aged 65 and above) and immunocompromised patients3.

**The recent findings significantly revealed that RSV and influenza A are the most prevalent fatal types in Hong Kong4.

 

Test name:

Influenza A/B & RSV Molecular Assay
(甲型, 乙型流感病毒及呼吸道合胞病毒快速分子測試)

Specimen requirement: Nasopharyngeal Swab in UTM transport medium
 Turn around time:  40 minutes

(upon the arrival of the specimen at the lab in Central or Wong Chuk Hang)

 

With best regards

 

Chan & Hou Medical Laboratories Limited